Newer insights into the management of interstitial lung disease in systemic sclerosis

Robert Mango, Jay H Ryu, Ashima Makol

Research output: Contribution to journalReview article

Abstract

Interstitial lung disease (ILD) is a debilitating complication of systemic sclerosis (SSc) and now the leading cause of death in SSc patients, largely from progressive respiratory failure or advanced pulmonary hypertension. Despite significant advances in our understanding of the epidemiology and pathogenesis of SSc-ILD, there are significant uncertainties in the approach to managing these patients given the heterogeneity of presentation, substantial variability in progression, and presence of comorbid cardiopulmonary conditions, particularly pulmonary hypertension and esophageal dilation with recurrent aspiration pneumonitis that portend poor prognosis. Early detection of progressive lung involvement based on worsening pulmonary physiology and quantification of fibrosing alveolitis severity on high-resolution computed tomography is critical as response to immunomodulatory agents is usually best when initiated earlier in the disease course. A selected group of patients may benefit from early referral for hematopoietic stem cell transplantation or lung/heart-lung transplant. The last decade has seen a significant advance in evidence-based approaches to treatment of SSc-ILD with immune suppressants, and there are several ongoing treatment trials with recent advances in understanding of the role of pro-inflammatory and profibrotic cytokines in SSc-ILD. The efficacy of antifibrotic agents in idiopathic pulmonary fibrosis has also provided another promising avenue for utilization in these patients. In this review, we will provide an up-to-date review of the treatment options for SSc-ILD, the ongoing studies moving this field forward, emerging treatments for SSc-ILD, and propose a management algorithm for SSc-ILD, based on the available evidence in the literature and our experience.

Original languageEnglish (US)
Pages (from-to)S194-S203
JournalIndian Journal of Rheumatology
Volume12
Issue number6
StatePublished - Nov 1 2017

Fingerprint

Systemic Scleroderma
Interstitial Lung Diseases
Lung
Pulmonary Hypertension
Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Hematopoietic Stem Cell Transplantation
Therapeutics
Respiratory Insufficiency
Uncertainty
Dilatation
Cause of Death
Pneumonia
Epidemiology
Referral and Consultation
Tomography
Cytokines
Transplants

Keywords

  • Antifibrotic treatment
  • connective tissue diseases
  • immunosuppressive agents
  • interstitial
  • interstitial lung disease
  • lung diseases
  • systemic sclerosis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Newer insights into the management of interstitial lung disease in systemic sclerosis. / Mango, Robert; Ryu, Jay H; Makol, Ashima.

In: Indian Journal of Rheumatology, Vol. 12, No. 6, 01.11.2017, p. S194-S203.

Research output: Contribution to journalReview article

@article{1ea964628fef480dae6411b52ea7539d,
title = "Newer insights into the management of interstitial lung disease in systemic sclerosis",
abstract = "Interstitial lung disease (ILD) is a debilitating complication of systemic sclerosis (SSc) and now the leading cause of death in SSc patients, largely from progressive respiratory failure or advanced pulmonary hypertension. Despite significant advances in our understanding of the epidemiology and pathogenesis of SSc-ILD, there are significant uncertainties in the approach to managing these patients given the heterogeneity of presentation, substantial variability in progression, and presence of comorbid cardiopulmonary conditions, particularly pulmonary hypertension and esophageal dilation with recurrent aspiration pneumonitis that portend poor prognosis. Early detection of progressive lung involvement based on worsening pulmonary physiology and quantification of fibrosing alveolitis severity on high-resolution computed tomography is critical as response to immunomodulatory agents is usually best when initiated earlier in the disease course. A selected group of patients may benefit from early referral for hematopoietic stem cell transplantation or lung/heart-lung transplant. The last decade has seen a significant advance in evidence-based approaches to treatment of SSc-ILD with immune suppressants, and there are several ongoing treatment trials with recent advances in understanding of the role of pro-inflammatory and profibrotic cytokines in SSc-ILD. The efficacy of antifibrotic agents in idiopathic pulmonary fibrosis has also provided another promising avenue for utilization in these patients. In this review, we will provide an up-to-date review of the treatment options for SSc-ILD, the ongoing studies moving this field forward, emerging treatments for SSc-ILD, and propose a management algorithm for SSc-ILD, based on the available evidence in the literature and our experience.",
keywords = "Antifibrotic treatment, connective tissue diseases, immunosuppressive agents, interstitial, interstitial lung disease, lung diseases, systemic sclerosis",
author = "Robert Mango and Ryu, {Jay H} and Ashima Makol",
year = "2017",
month = "11",
day = "1",
language = "English (US)",
volume = "12",
pages = "S194--S203",
journal = "Indian Journal of Rheumatology",
issn = "0973-3698",
publisher = "Elsevier (Singapore) Pte Ltd",
number = "6",

}

TY - JOUR

T1 - Newer insights into the management of interstitial lung disease in systemic sclerosis

AU - Mango, Robert

AU - Ryu, Jay H

AU - Makol, Ashima

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Interstitial lung disease (ILD) is a debilitating complication of systemic sclerosis (SSc) and now the leading cause of death in SSc patients, largely from progressive respiratory failure or advanced pulmonary hypertension. Despite significant advances in our understanding of the epidemiology and pathogenesis of SSc-ILD, there are significant uncertainties in the approach to managing these patients given the heterogeneity of presentation, substantial variability in progression, and presence of comorbid cardiopulmonary conditions, particularly pulmonary hypertension and esophageal dilation with recurrent aspiration pneumonitis that portend poor prognosis. Early detection of progressive lung involvement based on worsening pulmonary physiology and quantification of fibrosing alveolitis severity on high-resolution computed tomography is critical as response to immunomodulatory agents is usually best when initiated earlier in the disease course. A selected group of patients may benefit from early referral for hematopoietic stem cell transplantation or lung/heart-lung transplant. The last decade has seen a significant advance in evidence-based approaches to treatment of SSc-ILD with immune suppressants, and there are several ongoing treatment trials with recent advances in understanding of the role of pro-inflammatory and profibrotic cytokines in SSc-ILD. The efficacy of antifibrotic agents in idiopathic pulmonary fibrosis has also provided another promising avenue for utilization in these patients. In this review, we will provide an up-to-date review of the treatment options for SSc-ILD, the ongoing studies moving this field forward, emerging treatments for SSc-ILD, and propose a management algorithm for SSc-ILD, based on the available evidence in the literature and our experience.

AB - Interstitial lung disease (ILD) is a debilitating complication of systemic sclerosis (SSc) and now the leading cause of death in SSc patients, largely from progressive respiratory failure or advanced pulmonary hypertension. Despite significant advances in our understanding of the epidemiology and pathogenesis of SSc-ILD, there are significant uncertainties in the approach to managing these patients given the heterogeneity of presentation, substantial variability in progression, and presence of comorbid cardiopulmonary conditions, particularly pulmonary hypertension and esophageal dilation with recurrent aspiration pneumonitis that portend poor prognosis. Early detection of progressive lung involvement based on worsening pulmonary physiology and quantification of fibrosing alveolitis severity on high-resolution computed tomography is critical as response to immunomodulatory agents is usually best when initiated earlier in the disease course. A selected group of patients may benefit from early referral for hematopoietic stem cell transplantation or lung/heart-lung transplant. The last decade has seen a significant advance in evidence-based approaches to treatment of SSc-ILD with immune suppressants, and there are several ongoing treatment trials with recent advances in understanding of the role of pro-inflammatory and profibrotic cytokines in SSc-ILD. The efficacy of antifibrotic agents in idiopathic pulmonary fibrosis has also provided another promising avenue for utilization in these patients. In this review, we will provide an up-to-date review of the treatment options for SSc-ILD, the ongoing studies moving this field forward, emerging treatments for SSc-ILD, and propose a management algorithm for SSc-ILD, based on the available evidence in the literature and our experience.

KW - Antifibrotic treatment

KW - connective tissue diseases

KW - immunosuppressive agents

KW - interstitial

KW - interstitial lung disease

KW - lung diseases

KW - systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85046904712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046904712&partnerID=8YFLogxK

M3 - Review article

VL - 12

SP - S194-S203

JO - Indian Journal of Rheumatology

JF - Indian Journal of Rheumatology

SN - 0973-3698

IS - 6

ER -